Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs XPO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at XPO's multiple
Needs XPO P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · XPO FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
XPO, Inc. · implied price per share
Bear
$11.25
Base
$13.23
Bull
$15.22
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
1.83x
Net debt / EBITDA
Leverage against operating earnings
0.01x
3.47x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$310.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
C. H. ROBINSON WORLDWIDE, INC.
SRPT vs CHRW
Hub Group, Inc.
SRPT vs HUBG
SAIA INC
SRPT vs SAIA
OLD DOMINION FREIGHT LINE, INC.
SRPT vs ODFL
FEDEX CORP
SRPT vs FDX
UNITED PARCEL SERVICE INC
SRPT vs UPS
$934.46M
$3.41B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can materially improve margins and earn a sustained re-rating from its current negative profitability base, then the stock can be considered for a speculative value position because the current price is near the low end of its historical band and far below XPO-implied value; otherwise, the weak quality metrics argue for caution.
SRPT trades at 0.9x P/S versus XPO at 3.0x, which is the main reason the P/S-based implied price points to $62.18 versus the current $19.28. However, that gap is not a clean signal of undervaluation because SRPT's margins and returns are sharply negative while XPO is profitable.
Supporting Metrics
